Among all subtypes of breast cancer, the aggressive human epidermal growth factor 2-positive (HER2-positive) breast cancer, which is characterised by overexpressed or amplified HER2 receptor, accounts for approximately 20–30% of all annually diagnosed cases [2]. Here, ERBB2 is linked to breast cancer.